Showing results (61-70 of 137) with videos related to

Sort By:
Pageof 14
Pulmonary Circulation|April 25, 2012
Hypoxia modulates the expression of leucine zipper-positive MYPT1 and its interaction with protein kinase G and Rho kinases in pulmonary arterial smooth muscle cellsDev K Singh, Joy Sarkar, Aarti Raghavan, et al.
The Journal of Biological Chemistry|September 11, 2009
Direct regulation of prokaryotic Kir channel by cholesterolDev K Singh, Avia Rosenhouse-Dantsker, Colin G Nichols, et al.
Neurosurgical Review|August 25, 2019
A review of virtual reality simulators for neuroendoscopyBritty Baby, Ramandeep Singh, Ashish Suri, et al.
The Journal of Dermatology|January 25, 2024
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque, erythrodermic, or generalized pustular psoriasis: Efficacy and safety results from an open-label, phase 3 trialShinichi Imafuku, Yukari Okubo, Yayoi Tada, et al.
Arthritis Care & Research|September 25, 2019
Baseline Objective Inflammation by Magnetic Resonance Imaging as a Predictor of Therapeutic Benefit in Early Rheumatoid Arthritis With Poor PrognosisHarris A Ahmad, Joshua F Baker, Mikkel Østergaard, et al.
Rheumatology (Oxford, England)|October 18, 2024
Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: achievement of minimal disease activity components in a phase 2 trialArthur Kavanaugh, Laura C Coates, Philip J Mease, et al.
Molecular Neurobiology|May 2, 2024
Biochemical, Biomarker, and Behavioral Characterization of the Grn<sup>R493X</sup> Mouse Model of Frontotemporal DementiaDenise M Smith, Geetika Aggarwal, Michael L Niehoff, et al.
The New England Journal of Medicine|September 13, 2018
Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in PsoriasisKim Papp, Kenneth Gordon, Diamant Thaçi, et al.
The Journal of Rheumatology|December 17, 2015
Safety and Efficacy of Open-label Subcutaneous Ixekizumab Treatment for 48 Weeks in a Phase II Study in Biologic-naive and TNF-IR Patients with Rheumatoid ArthritisMark C Genovese, Daniel K Braun, Janelle S Erickson, et al.
The Journal of Biological Chemistry|May 30, 2014
Structure of REV-ERBβ ligand-binding domain bound to a porphyrin antagonistEdna Matta-Camacho, Subhashis Banerjee, Travis S Hughes, et al.
Pageof 14